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Abstract
Rats were depleted of skin histamine by more than 80 % by intraperitoneal injections of
sinomenine with daily increasing doses for 6 days. In these rats, egg-white edema induced in the
hind paws was inhibited by 68 % of control. The weight of the wall of granuloma pouch made
by croton oil was also evidently smaller in the rat treated similarly with sinomenine than that of
control. This suggests an important role of histamine participating in the inflammation. It has
been observed that a variety of non-steroidal anti-inflammatory drugs inhibited both degranula-
tion and histamine release induced by compound 48/80 of mast cells isolated from rat peritoneal
fluid. The degranulation inhibiting actions of anti-inflammatory drugs were markedly decreased
in the presence of glucose as in cases of dinitrophenol, dicumarol and warfarin which are known
uncouplers of oxidative phosphorylation. Also, prevention of edema provoked by anti-rat serum
is roughly correlated to a potency of degranulation inhibiting effect of anti-inflammatory agents.
These observations suggest that there is a common mechanism between these two phenomena,
and the prevention of mast cell degranulation by the anti-inflammatory agents is, at least, partially
due to their uncoupling effects. A working hypothesis explaining the process of edema forma-
tion at the inflammatory site has. been made based on the data of the present experiment and
other ob3ervations: a leakage of plasma into the tissue space from the gap between two adja-
cent endothelial cells which are contracted by released histamine may activate a kinin-forming
system in the plasma, and kinin(s) may further aggravate a leakage. The mechanism of action
of anti-inflammatory agents, which interfere with the histamine effect in inflammation, should be
understood in twofold: one is prevention of histamine release from the tissue, mainly by inhibiting
mast-cell degranulation, and the other is prevention of the contraction of endothial cells by their
uncoupling activities.
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Inflammation is a complex process involving many biochemical
changes with the participation of several mediators. Since a number of
factors should be considered, it is not easy to elucidate the role of a single
mediator in the development of inflammation. Although it has been
suggested that histamine plays an important role in inflammation, it is not
possible to explain the whole set of events only by histamine action.
In recent years, much attention has been turned to the other factors
participating in the inflammation, such as serotonin (l) and bradykinin
(2, 3). However, the degree of participation of each mediator is not the
same regarding the etiology of inflammation and also varies with the
species of animals (4). It has been mentioned that the common feature in
various types of experimental inflammation is in delayed, prolonged
permeability response, and histamine acts only in immediate, transient
response. This immediate response of histamine can be seen both in
rabbits and guinea pigs but not in rats (5). The present report concerns
the experiments performed by using the rat to see the degree of histamine
participation in experimental inflammation.
METHODS
Measurement of egg-white edema and its inhibition: Male albino rats weighing
100.,.150 g were used in this experiment because histamine content of the skin is
relatively constant in this weight range (6) and males are more sensitive to egg
white than females (7).
The egg-white edema was induced by the subcutaneous injection of 0.1 ml of
fresh egg white diluted ten times with 0.85 % saline solution into the dorsa of
the hind paw. The intensity of edema was measured with a micrometer gauge
with weakened spring and was represented as the difference of the dorso-planter
thickness in mm of hind paw before and after the injection of egg white. As the
edema could be produced in the same degree on both paws of one rat, one side
------------- --------------
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was used as control. On the day after the control edema was measured, edema
was produced on the other hind paw of the same rat administered with drug to
be tested. The percentage inhibition was calculated from the following equation:
(En-Et) 100/En, where En represents intensity of control edema (mm), and Et
(mm) is intensity of edema after drug administration.
Measurement of histamine release from the skin and its inhibition: A small piece
000-200 mg) of the skin on one side of the abdomen was excised aseptically under
light ether anesthesia. This was performed three days before the drug administ-
ration because this period is required for the recovery of the skin histamine con-
tents from the remote injury (8). Similar excision on the corresponding side was
made between 24 and 30 hr after the drug administration to determine the
histamine release from the skin. To determine the effect of drugs in inhibiting
the histamine release, 3600 mg/kg of dextran was injected intraperitoneally in
one group, and in another group a drug to be tested was administered before
dextran injection. The perc.entage reduction of skin histamine in these two
groups was compared. Extraction and bioassay of histamine were made by the
methods described by SANUKI (9). The histamine content was expressed by the
weight of the base.
Granuloma poueh: Fifteen milliliters of air was injected into the subcutaneous
connective tissue between the shoulder blades of male albino rats weighing 100-
130 g and 1 ml of 0.5 % croton oil dissolved in corn oil was injected into a result-
ing air space. For the measurement of intensity of inflammation, total weight
of the pouch was measured. The pouch wall was stripped off from the skin and
underlying tissues cautiously, and the oval pouch containing an exudate was
extirpated. After an exudate was removed, the pouch was weighed. To deter-
mine histamine content, 0.2-0.5 g of the tissue specimen was taken from the
pouch wall.
Anti-inflammatory aSS{~y: Evaluation of anti-inflammatory effect was made by
the punch method devised by UNGAR et al. (10), in which anti-inflammatory effect
of drug is determined by measuring the inhibition of cutaneous edema provoked
by antiserum. Male Wistar rats weighing about 150 g were used in this experiment.
Each animal was injected with the lyophilized anti-rat rabbit serum 5 mg in 0.05
ml normal saline, adjusted to pH 7.2, per site intracutaneously on the shaved skin
of the back, 4 sites on one side, while in corresponding 4 sites on the other side
saline injection of the same quantity was made. Two hr after the injection of
antiserum, when the edema reached its maxium, the animal was stunned and
exsanguinated. The removed back skin was pinned on a board and injected sites
were cut with a steel punch. Each piece of skin, 112 mm2, was weighed immedi-
ately after removal. Intensity of inflammation was expressed as follows: (Wi-Ws)
100/Ws, where Wi is the weight of the inflamed site and Ws is the weight of the
saline injected site. Sixty-four experiments on sixteen control animals gave a mean
of 89±0.68 (S. E.). Anti-inflammatory activity was expressed as per cent inhibition
of inflammation: (Ie-It) 100/Ie, where Ie is intensity of inflammation in the
control animal and It is the intensity in the animal treated with the drug. Drugs
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were usually administered intramuscularly 2 or 3 hr before the injection of anti-
serum and animal was killed 2 hr later. In cases of testing the effects of metabolic
inhibitors, antiserum injection was given 30 min after adminstration of inhibi.
tors.
Experiments on mast cells: After exsanguination of Wistar rats of either sex
weighing 150-300g, 5 ml of buffered physiological solution containing 0.1 % w/v
bovine serum albumin were injected into the peritoneal cavity and gentle massage
of the abdominal wall was done for 90 sec. The mast cells were isolated from
peritoneal fluid by differential centrifugation using a 37 % (w/w) solution of bovine
serum albumin. They were suspended in a physiological buffer s6iution and kept
on ice before use. Mast cells (0.5-1 X 106) were suspended in 0.95 ml of the buffer
solution either in the presence or absence of the drug and incubated for 15 min
at 37°C. After addition of 0.05 ml of compound 48/80 to make the concentration
of 0.5 ,ug/ml, incubation was continued for another 15 min. At the termination
of incubation, mast cells were fixed with 4 % formaldehyde. Morphological
changes were observed by means of the invert-type phase contrast microscope,
and percentage of degranulated mast cells was estimated. Inhibitory effect of
the drug was calculated from (A-B) 100/A, where A and B are the percentages
of degranulated mast cells in the media with and without drug, respectively.
To determine histamine release from mast cells, the mast cell suspension in.
cubated with compound 48/80 was centrifuged for 10 min at 5000 Xg in a refrige-
rated centrifuge. A few drops of water were added to the precipitate containing
mast cells. After freezing and thawing it was diluted with buffer solution. Hista-
mine in the supernatant and the precipitate was determined on atropinized
guinea-pig ileum. None of the drugs tested interfered with histamine assay at the
concentrations used in the present experiment.
RESULTS
1. Histamine depletion and inhibition of egg-white edema
Sinomenine is an alkaloid derived from the roots of Sinomenium acutum
REHDER et WILSON. A single intraperitoneal injection of this compound
caused a marked reduction of histamine content in the abdominal skin of
the rat, especially in the inner layer of the skin. When sinomenine was
injected intraperitoneally to rats for 6 consecutive days, twice a day start-
ing with 50 mg/kg and increasing daily dose by 100 mg/kg, an average
of 88.2 % reduction of histamine content in the abdominal skin was
achieved. Symptoms attributable to the released histamine, such as red-
dening around the ears, snout, sole of paws and genital areas, itching
of the face, sometimes cyanosis accompanied by severe dyspnea and pros-
tration, were observed. But, during the repeated injections appearance of
these symptoms decreased gradually in spite of increasing dose.
In those animals depleted the skin of histamine anaphylactoid edema
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TABLE I INHIBITION OF EGG-WHITE EDEMA OF THE HIND-PAW AND REDUCTION OF HISTAMINE
OF THE ABDOMINAL SKIN OF RAT BY HISTAMINE RELEASERS. EGG-WHITE EDEMA WAS INDUCED
24 HR AFTER THE END OF INJECTIONS OF SINOMENINE, 48/80 AND DEXTRAN
Drug mg/kg No. of rats Edema inhibition Histamine reduction
(i.p.) (%) (%)
Sinomenine 50 6 45.6±1.6 32.5±3.7
Sinomenine 500* 6 62.9±2.6 39.8±2.7
Sinomenine 2 lOOt 6 68.4±1.3 88.2±2.0
48/80 I 6 24.3±2.0 18.4±0.78
Dextran 3600 6 43.0±2.9 30.4±3.5
* 50 mg/kg X 2, for 5 days.
t 50 to 300 mg/kgX2, daily increasing for 6 days.
induced by egg white in the hind paws was markedly inhibited. Table 1
shows histamine depletion and inhibition of egg-white edema in rats receiv-
ing a single intraperitoneal injection of 50 mg/kg of sinomenine, 1 mg/kg
of compound 48/80 and of 3600 mg/kg of dextran and also after consec-
utive injections of sinomenine to the total doses of 500 mg/kg and 2100
mg/kg. In the latter two groups, inhibition of edema was more than
60 %. As far as these three compounds are concerned, there is a rough
correlation between histamine depletion and edema inhibition.
2. Edema inhibition in association with prevention of histamine release by some
anti-inflammatory drugs
Table 2 shows the effects of some anti-inflammatory drugs on the
histamine content and the inhibition of edema when these drugs were
given intraperitoneally one hr before the egg-white injection to the hind
paw. Although all of them had some inhibitory effects in greater or lesser
extent on the eaema formation, none of them showed a significant reduc-
tion of the histamine content. Similar experiments performed with dextran
alone and simultaneous administration with some anti-inflammatory agents
TABLE 2 INHIBITION OF EGG-WHITE EDEMA OF THE HIND-PAW AND CHANGE IN HISTAMINE
CONTENT OF THE ABDOMINAL SKIN BY ANTI-INFLAMMATORY DRUGS. DRUGS WERE INJECTED
I HR BEFORE EDEMA PRODUCTION
Drug
Sod. salicylate
Aminopyrine
Butazolidine sod.
Cortisone
Guaiazulene
Guaiazulene
Guaiazulene
mg/kg
(i. p.)
250
100
100
100*
200
100
50
No. of rats
6
6
6
6
6
6
6
Edema inhibition
(%)
26.2±1.2
28.1 ±2.4
26.0± 1. 7
18.2± 1.4
51.6±1.6
24.9±2.3
18.1±2.3
Change of histamine content
(%)
O±I.l
0.6 ±O. 97 (increase)
0.4±0.72 (increase)
6.6±1.4 (increase)
4.0 ± 2.3 (increase)
* 50 mg/kg (i. m.) 24 hr and I hr before edema.
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TABLE 3 EFFECTS OF ANTI-INFLAMMATORY DRUGS ON THE EDEMA INHIBITION (HIND PAWS)
AND THE HISTAMINE REDUCTION (ABDOMINAL SKIN) INDUCED BY DEXTRAN
No. of Edema Histamine No. of HistamineDrug (mg/kg)* inhibition reduction reduction
rats t (%) (%) rats :\: (%)
Dextran (3600) alone 6 43.0±3.0 30.1 ±4.2 6 30.4±4.2
Sod. salicylate (250)+ Dextran (3600) 6 57.2±2.8 4.3 ± 1.8 6 1O.2±1.6
Aminopyrine (l00) + // 5 54.9±3.3 18.5 ±3.5 6 20.8±1.2
Cortisone (l00) + // 6 59.6±2.2 13.9 ±2.5 6 15.9± 1.2
Guaiazulene (100) + II 5 5I.5±3.7 § 0.27±2.7 6 17.3±2.1
Phenergan (5) + // 6 46.1±I.9§ 15.9±1.9 6 21. 7±2.5 §
* Dextran was injected intraperitoneally.
t In these series of experiments sodium salicylate, amino)yrine and guaiazulene were given
intraperitoneally I hr before, phenergan subcutaneously 30 min before dextran, corti-
sone intramuscularly 50 mg/kg, 24 hr and also 1 hr before dextran.
:\: In these series cortisone was given 50 mg/kgX2, 48 and 24 hr, and the other drugs 24
hr before dextran by similar routes in the t series.
§ No significant difference from the effect of dextran alone at the value of P as 0.05.
are shown in Table 3. Histamine depletion by dextran alone was evidently
reduced when these anti-inflammatory agents were given simultaneously.
On the contrary, edema inhibition of dextran was clearly enhanced by
simultaneous administrations of these drugs. The results so far mentioned
suggest that there are at least two mechanisms in inhibiting edema forma-
tion; one is the histamine depletion from the tissue and the other is due to
the prevention of histamine release.
3. Granuloma pouch
Granuloma pouch technique described by SELYE was employed as the
other means of studying acute inflammation. Since croton oil disrupts
mast cells of the rat skin more drastically than egg white (II), this material
may be suitable for studying the role of histamine in a severe inflammation.
To know the detailed histamine participation in this inflammation, follow-
ing experimental schedules have been made. The experiment was carried
out on 5 groups, each with 2-5 animals. Experimental schedule in each
group is shown in Fig. I: (a) is non-treated control, (b) is sinomenine-
treated, (c) is sinomenine and cortisone-treated, (d) is histamine-treated
and (e) is aminoguanidine-treated group. The dosage and period of the
drug administration in each group are shown in Fig. 1.
Histamine contents in the abdominal skin after the pouch formation
are shown in Fig. 2. The mean value of 37 /J.g/g in the control group was
almost the same as that obtained from normal rats. Both in histamine-
treated and aminoguanidine-treated groups, histamine contents of the
skin were almost twice of the normal value. On the contrary, in the
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Twice daily
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2 3 4 5 6 7 8 9 10 I I 12 13 14 15 Days
Fig. I Scheme of experimental design. a) control, b) sinomenine-treated,
c) sinomenine and cortisone-treated, d) histamine-treated, and e) aminoguanidine-
treated. At arrow, granuloma pouch was made.
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Fig. 2 Effects of repeated daily injections of sino:nenine, sinomenine plus
cortisone, histamine and aminoguanidine on the histamine content of the abdomi-
nal skin after granuloma pouch formation.
sinomenine-treated and in the sinomenine and cortisone-treated groups, the
values were less than one third of the control value. It is noticed that the
changes of mean values in all groups dropped in fairly narrow range after
the formation of granuloma pouches. Especially, the fact that the mean
value of histamine content in the control group differed not much from
the normal value indicates that formation of the pouch did not change
the skin histamine remarkably.
Fig. 3 shows the time course of changes in histamine content of the
pouch wall in different groups. These changes, in general, are similar to
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Fig. 3 Time course of changes in histamine content of the pouch wall dur-
ing the repeated daily administrations of sinomenine, sinomenine plus cortisone,
histamine and aminoguanidine
those of the skin histamine contents. However, after the fourth day the
values declined gradually in both the histamine- and aminoguanidine-treat-
ed groups and also in the control group. The reason for such a decrement
may simply be due to edematous swelling, not causing decrease in the
total histamine amount (cf Fig. 4).
The variation in the weight of the pouch wall in different groups is
shown in Fig. 4. In the control group, the high values were shown from
the 4th to the 6th day. The weights of the pouch wall both in the sinome-
nine-treated and sinomenine and cortisone-groups were remarkably smaller
50
40
..... )( 5 inomenlOe
Cortisone
20
I
101
i
0 1 --'--__-'--__'----
DAYS
Fig. 4 Changes in weight of the granuloma pouch wall during the consec-
utive daily administrations of sinomenine, sinomenine plus cortisone, histamine
and aminoguanidine.
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than that of control. The weight of the pouch wall in histamine-treated
group was also less than that of the control group. A decreased reactivity
to histamine after its desensitization may be the reason for inhibition of
edema formation.
4. Inhibition of mast-cell degranulation
a. Anti-inflammatory agents and related compounds
Dose-response relationship of the inhibitory effect of some anti-inflam-
matory agents on mast-cell degranulation induced by compound 48/80
is shown in Fig. 5. Oxyphenbutazone was the most potent inhibitor in
I Ox yphenbutazone
2 Flufenamic acid
3 2.4-Dinitrophenol
'4 Phenylbutazone
5 Mefenamic acid
6 IndomethaCIn
7 Sulf inpyrazone
8 C inchophene
9 Glycyrrhizin
10 Sodium salicylate
I I Aminopyrine
I 2 Prednisolone sodium succinate
13 Hydrocor tisone sodium succinate
- no glucose
-.----. with glucose
80
60
40
20
- -'. -~ ~ - --_.-
o '-----:O:-:O:-::O::-:25::--:0:-::0:-::-l'5~-:::O--::-O:--,,'7('~:-::)5-0::-:.0:-:-5-"""O:"'I--O"""2C::-5-C::-OOj..S:':'--I.!...O--~2·:;"'·~-""'5-0--IOO
CONCENTRATION-mM (log scale)
Fig. 5 Dose-response relationship of inhibitory activity of sorr.e anti-inflammatory
drugs on mast-cell degranulation in the presence and absence of glucose (5.6 mM).
Each point is the mean of at least 4 determinations.
this experiment either with or without glucose (5. 6 mM). Marked inhibitory
effects were also seen in flufenamic acid, phenylbutazone, mefenamic
acid and indomethacin decreasing in potency in that order. Especially in
indomethacin, superior inhibition was noticed rather in lower concentra-
tions. In general, the presence of glucose in the medium lowered the
inhibitory effect of the anti-inflammatory agents.
b. Inhibition of histamine release from mast cells
Fig. 6 shows both mast-cell degranulation and histamine release in-
duced by compound 48/80 are being inhibited by pretreatment with phenyl-
butazone and sodium salicylate. Percentages of inhibitions of histamine
release and of degranulation run parallel with the variance of drug con-
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Fig. 6 Parallel inhibition by phenylbutazone and sodium salicylate of mast-
cell degranulation and histamine release induced by compound 48/80 (0.5/lg/ml)
in the absence of glucose.
Degranulation (.--.); histamine release (0-- 0); inhibition of degranula-
tion ( ); inhibition of histamine release (0 0).
centration, indicating that these drugs inhibit the morphological changes
in mast cells leading to the release of histamine.
c. A1etabolic inhibitors
See Table 4. Mast-cell degranulation by compound 48/80 was
TABLE 4 EFFECTS OF METABOLIC INHIBITORS ON MAST-CELL DEGRANULATION BY
COMPOUND 48/80 AND ON INFLAMMATORY EDEMA BY ANTISERUM
Anti-inflammatory effect
Drug
Cone. of 50 %
inhibition of M. C.
degranulation
No With
glucose glucose*
mM mM
Dose
mg/kg
Reduction of
weight increase
%±S.E.
a. Inhibitors of respiration or oxidative
phosphorylation
2,4-Dinitrophenol 0.02 1.2 30 26±0.9 (38±1.1 t)
Dicumarol 0.02 0.5 30 15±1.4 (32±1.0t)
Warfarin sodium 0.16 6.0 30 33±0.8 (38±0.5t)
Amytal sodium 0.5 2.6 30 30± 1.1
b. Inhibitors of glycolysis or glucose
transport
Phlorizin <LOt 30 50± 1.0
2-Deoxyglucose 5.6t 250 39± 1.1 t
Iodoacetate 0.5 0.5 30 42±O.8
Sodium fluoride 1O§ 30 50±0.9
• 5.6 mM.
Injected s. c. 30 min before antiserum, while all the others were injected i. m. 2 hr
before.
Under anaerobic condition.
Under anaerobic condition, in Ca2+·free medium.
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inhibited when pretreated with low concentrations of 2, 4-dinitrophenol,
dicumarol and warfarin which are known as uncouplers of oxidative
phosphorylation. Amytal, a respiratory inhibitor, also produced a moderate
inhibition. These inhibitions were largely enervated in the presence of
glucose as in the cases of inhibition by anti-inflammatory agents (Fig. 5).
Mast cells cannot be degranulated by compound 48/80 when oxygen is lack-
ing, but this inability is reversed when glucose is present in the medium. This
indicates that glycolysis is one of the suppliers of energy required for the
mechanism of mast-cell degranulation. Some of the inhibitors of glycolysis
or glucose transport could also inhibit mast-cell degranulation by 48/80 in
the glucose containing medium in anoxia (Table 4, b). These results imply
that at least a part of the inhibitory effect, abolished in the presence of
glucose, of anti-inflammatory agents on mast-cell degranulation may con-
cern the glucose dependent action which escaped likewise from the inhibitory
action' of uncouplers or respiratory inhibitors by the presence of glucose.
Actually, some anti-inflammatory drugs such as salicylate, indomethacin
and phenylbutazone are known as inhibitors of oxidative phosphorylation
as reported by ADAMS and COBB (12) and also by WHITEHOUSE (13).
5. Anti.inflammatory effect
a. Anti-inflammatory agents and related compounds
Among salicylates and related compounds in the present test, sodium
salicylate, acetylsalicylic acid and 2, 5-dihydroxybenzoic acid were effective
in inhibiting mast-cell degranulation. These compounds also moderately
inhibited the inflammatory edema induced by anti.rat serum by 43, 33
and 30 %, respectively as shown in Table 5. To our interest, while salicylic
acid and 2, 5-dihydroxybenzoic acid were effective inhibitors of mast-cell
degranulation and of inflammatory edema, m- and p-isomers of salicylic
acid, and 2, 4-, 2, 6· and 3, 5.dihydroxybenzoic a<;:ids were all less effective
in inhibiting either reaction.
Of the pyrazolone derivatives, sulfinpyrazone, oxphenbutazone, phenyl-
butazone and aminopyrine showed marked anti-inflammatory effects,
while antipyrine and 4-aminoantipyrine were ineffective. Among non-
steroidal agents, indomethacin had the most potent anti-inflammatory
activity followed in order by mefenamic acid, glycyrrhizin and chloro·
quine phosphate. Prednisolone was the most effective anti-inflammatory
agent tested in the present experiment. These results show that there is
a gross correlation between anti-inflammatory effect' and degranulation-
inhibiting effect in many drugs tested, except chloroquine, aminopyrine
and the glucocorticoids which showed disproportionally strong anti-edema
effect compared to the weak inhibition on mast-cell degranulation.
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TABLE 5 EFFECTS OF ANTI-INFLAMMATORY AGENTS AND RELATED COMPOUNDS ON MAST-:::ELL
DEGRANULATION BY COMPOUND 48/80 AND ON INFLAMMATORY EDEMA BY ANTISERUM
Conc. of 50%
inhibition of M. C. Anti.inflammatory. effect
Drug degranulation
No With Dose Reduction ofglucose glucose* weight increase
mM mM mg/kg %±S.E.
a. Salicylates and related compounds
Sodium salicylate 1.5 7.2 250 43±0.5
Acetylsalicylic acid 1.1 2.8 250 33±1.0
Salicylamide 1.0 5.0 250 20±0.6
m-Hydroxybenzoic acid 16 30 250 23± 1.5
p-Hydroxybenzoic acid 17 18 250t 19±1.1
2,5-Dihydroxybenzoic acid 0.9 2.8 250 30±1.9
2,4-Dihydroxybenzoic acid 7.8 29 250 13±1.3
2,6-Dihydroxybenzoic acid 2.5 5.2 250 23±1.0
3,5-Dihydroxybenzoic acid 5.2 29 250 14±1.7
5-Sulfosalicylic acid 17 17 250 11 ±O. 7
p-Aminosalicylic acid 2.0 2.3 250 9±1.3
Thiosalicylic acid 0.7 2.0 30 9±0.7
Salicylaldehyde 0.07 1.9 250 18±0.7
Benzoic acid 11 16 250t 16±1.4
b. Pyrazolone derivatives
Antipyrine 16 16 30 7±1.1
250 22±0.9
Aminopyrine 2.4 15 30 38±0.4
4-Aminoantipyrine 5.4 17 30 9±1.0
Phenylbutazone 0.03 0.15 30 48±1.1
Oxyphenbutazone 0.006 0.007 30t 52±0.5
Sulfinpyrazone 0.12 0.24 30t 36±I.3
c. Other non-steroid agents
Anthranilic acid 7.8 28 30 27±2.0
Flufenamic acid 0.018 0.07 30 40±2.0
Mefenamic acid 0.062 0.23 30 49±1.3
Indo:nethacin 0.05 0.19 30t 57±1.3
Glycyrrhizin 0.46 30 46±2.2
Cinchophen 0.55 1.6 250 30±1.4
Chloro:Juine phosphate 3 3.6 25t 42±1.2
d. Glucocorticoids
Hydrocortisone sodium succinate 2.1 6.4 30 47±1.1
Prednisolone sodium succinate 1.6 3.8 5 47±0.7
* 5.6mM.
Injected i. m. 3 hr before antiserum, while all the others were injected 2 hr before.
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b. Effect of metabolic inhibitors
In relation to the assumption that the effects of some anti-inflammatory
agents may be due partially to the property as uncoupler of oxidative
phosphorylation, the anti-inflammatory effect of some typical uncouplers
was investigated. As shown in Table 4, DNP, dicumarol, warfarin and
amytal sodium produced a considerable anti-inflammatory effect at the
dose of 30 mg/kg. Fig. 7 shows the time course of the anti-inflammatory
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Fig. 7 Time course of inhibitory effect of some metabolic inhibitors and
anti-inflammatory drugs on inflammatory edema induced by antiserum. Ordi-
nate: Per cent reduction in weight increase of skin induced by antiserum. Abs-
cissa: Time intervals at which antiserum was injected after intramuscular or
subcutaneous administration of drugs.
effect of some metabolic inhibitors on the edema induced by antiserum
injection. The effects of DNP and dicumarol are short lived both in subcu-
taneous and intramuscular injections, reaching maximum effects within 30
min after injection. The transient effect of DNP may be due to the rapid
biotransformation to inactive metabolites such as 2-amino-4-nitrophenol,
which are weaker uncoupling agents, in the body (14).
DISCUSSION
From the results of experiment in egg-white edema, it is suggested
that there are at least two mechanisms in inhibiting egg-white edema: one is
the histamine depletion and the other is the prevention of histamine release
from the tissue. With a single dose of sinomenine, compound 48/80 and
dextran, edema inhibition was effected roughly in parallel with histamine
depletion from the skin; and consecutive sinomenine injections gave more
than 60 % inhibition. Edema inhibition after histamine depletion from
the tissue seems to provide circumstantial evidence for histamine participa-
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tion in the inflammation, even though it may not be free from some critical
points as follows: 1) it is very difficult to release the whole tissue hista.
mine and this hinders clear cut understanding of the role of histamine in
inflammation; 2) some other mediators such as serotonin may be released
at the inflammatory site, although this seems to be minor possibility as
discussed later; 3) the non-specific action of histamine releaser itself can
not be dismissed.
It has been shown that in the sinomenine-treated group the weight of
the granuloma pouch was remarkably smaller than that of the control
group. In the histological examination, vasodilatation and exudation were
strongly inhibited in the pouch wall accompanied by a slight leukocyte emig-
ration in sinomenine-treated group (15). This fact suggests an important
role of histamine in producing these inflammatory reactions. Sinomenine
may also release serotonin, because compound 48/80 which is a strong basic
histamine liberator like sinomenine is known to liberate these two amines
simultaneously (16). However, the fact that leaking of blue dye at the site
of intradermal injection of sinomenine was almost identical even after reser-
pinization in rats, while it was weakened in the case of 48/80 and dextran
(17), seems to contradict such a possibility. This agrees with the finding of
STERN and N IKUUN (18) who observed that the histological structure of the
granuloma pouch remained unchanged after depletion of serotonin, while
depletion of histamine caused marked change. From this observation, they
emphasized principally the active role of histamine in inflammatory process,
especially in dilatation and permeability increase of the vessels. The data
presented in the experiment on isolated rat mast cells show that there are at
least two different types of anti-inflammatory effects in anti-inflammatory
agents. One is prevention of mast-cell degranulation induced by compound
48/80 and the other is inhibition of edema induced by anti·rat serum. Since
these two effects are roughly correlated in most of the drugs tested and
also uncouplers of oxidative phosphorylation simulate these two effects
of anti.inflammatory agents, it is suggested that there is a mechanism
common to these two effects which are both energy dependent. Actually,
some anti.inflammatory agents such as salicylate, indomethacin and
phenylbutazone are reported as inhibitors of oxidative phosphorylation.
However, there are a few exceptional drugs showing disproportionally
potent edema inhibition compared to their weak degranulation-preventing
effects. Even in such drugs, inhibition of histamine release was remark.
ably noticed. Marked inhibition of histamine release provoked by dextran
was shown under the effects of cortisone, as well as prednisolone, hydro-
cortisone and dexamethasone, in the rat (19). It is known that histamine
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release caused by an exposure to antigen of sensitized tissues was inhibited
by sodium salicylate (20, 21). The mechanism of anti-edema effect of
chloroquine phosphate is possibly, at least in part, related to its anti·hista.
minic action (22) in interfering with the contraction of the endothelial cells
by released histamine. There are microscopic and electron microscopic
findings (23, 24) showing a wide opening of intercellular space between
two adjacent endothelial cells which become globular in form responding
to histamine and some other injurious stimulations. It may not be un-
reasonable to assume that this morphological change of endothelial cells is
energy dependent. SPECTOR (25) has pointed out the fact that all pharma-
cologically active agents increasing the permeability of capillary, contract
the smooth muscle. SPECTOR (25) and McLEAN, AHMED and JUDAH (26)
speculated that these active substances contract the endothelial cells and
provoke a leakage of the plasma. It is known that all the materials
necessary for a kinin formation are contained in the plasma and simple
matters such as dilution of the plasma or its contact to foreign bodies
activate the Hageman factor and this motivates a kinin formation.
On the basis of speculation referring to the data so far presented and
the proposal of other investigators a scheme shown in Fig. 8 is postulated.
SkinTissue spaceBlood
Endothelial Basement
,." ~ .,_.,m.. ~ I ..AID---~""', Hista~"ne ~---~-'lI'-H,stami,ne
'1<, Mast cell~I ; ," ,'. I; ••:.. _"_----- Histamine releasers81 d ;: Blood plasma ••: .....:. ~l00 " ; :'1 ••••:.. ~ Istream ,~ •• . --_ Burns at ,85 C. dog
~I ' Actlva,t',on of - (G,P,Lew,s. 1964)Kinin· forming system~AID~~.~
AID: Anti-inflammatory drugs
Fig. 8 Presumed mechanisms of acute inflammatory responses and their
inhibition bl anti-inflammatory drugs of uncoupler type.
At the primary stage of inflammation, histamine, and some other possible
factors such as serotonin, are released from the tissue and histamine acts
upon the endothelium of the capillary and widens the gap between two
adjacent endothelial cells. This may cause a leakage of blood plasma into
the tissue space and a kinin-formin~ system in the plasma may be activated
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in the tissue space. If this were the case, a kinin formed in such a sequence
further acts upon the capillary and produces an additional leaking. Thus,
a vicious circle starts. If these events really do occur, then histamine is
a primary mediator initiating a kinin formation as proposed by LEWIS
(27) in his demonstration with a dog foot. From these considerations, it is
clear that an inhibition of histamine release by anti-inflammatory agents
will be one of the important mechanisms in displaying their effects. Un-
coupler type anti-inflammatory agents may exert their effects by prevent-
ing the contraction of the endothelial cells in a manner to lessen an energy
supply.
SUMMARY
Rats were depleted of skin histamine by more than 80 % by intra-
peritoneal injections of sinomenine with daily increasing doses for 6 days.
In these rats, egg-white edema induced in the hind paws was inhibited by
68 % of control. The weight of the wall of granuloma pouch made by
croton oil was also evidently smaller in the rat treated similarly with sino-
meni-ne than that of control. This suggests an important role of histamine
participating in the inflammation.
It has been observed that a variety of non-steroidal anti-inflammatory
drugs inhibited both degranulation and histamine release induced by
compound 48/80 of mast cells isolated from rat peritoneal fluid. The
degranulation inhibiting actions of anti-inflammatory drugs were markedly
decreased in the presence of glucose as in cases of dinitrophenol, dicumarol
and warfarin which are known uncouplers of oxidative phosphorylation.
Also, prevention of edema provoked by anti-rat serum is roughly correlated
to a potency of degranulation inhibiting effect of anti-inflammatory agents.
These observations suggest that there is a common mechanism between
these two phenomena, and the prevention of mast cell degranulation by
the anti-inflammatory agents is, at least, partially due to their uncoupling
effects.
A working hypothesis explaining the process of edema formation at
the inflammatory site has. been made based on the data of the present
experiment and other ob3ervations: a leakage of plasma into the tissue
space from the gap between two adjacent endothelial cells which are
contracted by released histamine may activate a kinin-forming system in
the plasma, and kinin(s) may further aggravate a leakage. The mechanism
of action of anti-inflammatory agents, which interfere with the histamine
effect in inflammation, should be understood in twofold: one is preven-
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tion of histamine release from the tissue, mainly by inhibiting mast-cell
degranulation, and the other is prevention of the contraction of endothial
cells by their uncoupling activities.
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